|
|
Article: Operating income up 21% at Kyowa Hakko.(Kyowa Hakko Kogyo)(Financial report)
- Article from:
- Pharma Marketletter
- Article date:
- February 4, 2008
CopyrightCOPYRIGHT 2008 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
For the nine months from April 1 to December 31, 2007, net income at Japanese drugmaker Kyowa Hakko Kogyo was 24.0 billion yen ($225.4 million), or 60.55 yen per share, up 111.5% on the earnings achieved in the comparable period of its 2006 fiscal year. Operating income at the Tokyo-headquartered firm also improved, climbing 20.6% to 32.4 billion yen.
Navelbine drives pharmaceutical revenues
Sales for the period rose 11% to 297.0 billion yen, with an expanded contribution from key drug products such as Allelock (olopatadine HCl), Navelbine (vinorelbine) and the anti-allergic opthalmic solution ...